Infant Bacterial Therapeutics AB (publ)

OM:IBT B 株式レポート

時価総額:SEK 514.6m

Infant Bacterial Therapeutics 過去の業績

過去 基準チェック /06

Infant Bacterial Therapeuticsの収益は年間平均-22.2%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間12.9% 74.5%割合で 増加しています。

主要情報

-22.2%

収益成長率

-18.4%

EPS成長率

Pharmaceuticals 業界の成長30.5%
収益成長率74.5%
株主資本利益率-70.6%
ネット・マージン-2,880,640.0%
次回の業績アップデート13 Feb 2025

最近の業績更新

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02
Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

収支内訳

Infant Bacterial Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

OM:IBT B 収益、費用、利益 ( )SEK Millions
日付収益収益G+A経費研究開発費
30 Sep 240-14424130
30 Jun 240-14220133
31 Mar 240-12814126
31 Dec 230-12315120
30 Sep 230-1227122
30 Jun 230-99599
31 Mar 230-69467
31 Dec 220-65165
30 Sep 220-42140
30 Jun 220-34132
31 Mar 220-65163
31 Dec 210-45144
30 Sep 210-55154
30 Jun 210-74173
31 Mar 210-73172
31 Dec 200-72171
30 Sep 200-73172
30 Jun 200-65164
31 Mar 200-44144
31 Dec 190-46146
30 Sep 190-43143
30 Jun 190-40139
31 Mar 190-32130
31 Dec 180-41138
30 Sep 180-26124
30 Jun 180-22121
31 Mar 180-37136
31 Dec 170-36135
30 Sep 170-41141
30 Jun 170-44-247
31 Mar 170-42-244
31 Dec 160-38-240
30 Sep 160-19-130
30 Jun 160-7324
31 Mar 1600318
31 Dec 1500317
31 Dec 140007

質の高い収益: IBT Bは現在利益が出ていません。

利益率の向上: IBT Bは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: IBT Bは利益が出ておらず、過去 5 年間で損失は年間22.2%の割合で増加しています。

成長の加速: IBT Bの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IBT Bは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 8.9% ) と比較することは困難です。


株主資本利益率

高いROE: IBT Bは現在利益が出ていないため、自己資本利益率 ( -70.59% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘